[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 21, 2006

Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer

Author Affiliations

Author Affiliation: Division of Hematology/Oncology and Lynn Sage Breast Cancer Program, Northwestern University Feinberg School of Medicine (Dr Gradishar); and Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Dr Cella), Chicago, Ill.


Published online June 5, 2006 (doi:10.1001/jama.295.23.jed60037).

JAMA. 2006;295(23):2784-2786. doi:10.1001/jama.295.23.jed60037

This year, more than 200 000 women in the United States will be diagnosed as having invasive breast cancer.1 The past 20 years of research translating an understanding of basic biology into therapeutics has led to major improvements in the survival and quality of life of patients who carry a diagnosis of breast cancer. Parallel strategies to prevent breast cancer have also been studied. These include lifestyle modification (eg, diet, alcohol intake, optimizing weight, exposure to exogenous estrogens), ablative surgery (prophylactic mastectomy, oophorectomy, or both), and more recently, chemoprevention with selective estrogen receptor modulators (SERMs) such as tamoxifen.